Medication info
Crovaz 5mg (Rosuvastatin Calcium)

Crovaz 5mg (Rosuvastatin Calcium)

Prescription medicationTabletOral
Ingredient · strength
Rosuvastatin Calcium›5.2mg / 1 tablet
Manufacturer / importer
Daewon Pharmaceutical Co., Ltd.
Appearance
Yellow round film-coated tablet
Packaging
Domestic: 28 tablets (14 tablets/PTP X 2), Export: 28 tablets (14 tablets/PTP X 2)
Approval status
Active

MFDS item code 201400429 · Approved 2014.01.29 · Insurance code 671805690

Summary

Main use
Treatment of dyslipidemia, inhibition of atherosclerosis progression, and prevention of cardiovascular disease
Who takes it
Adults · Children
Adult dose
1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medication and continue it throughout the treatment period. This medication may be taken at any time of day, with or without food. The initial dose is 5 mg once daily. If a greater reduction in LDL cholesterol is required, the dose may be adjusted to a maintenance dose. The maintenance dose is 10 mg once daily, which controls the condition in most patients. The maintenance dose should be adjusted as appropriate at intervals of 4 weeks or more according to LDL cholesterol levels, treatment goals, and the patient's response, and may be increased to a maximum of 20 mg per day. 3. Elderly patients : No dosage adjustment is necessary. 4. Patients with renal impairment : No dosage adjustment is necessary for patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Particular caution should be exercised when administering 20 mg of this medication to patients with moderate renal impairment. 5. Patients with hepatic impairment : No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer this medication to patients with active liver disease. 6. Race : Because systemic exposure to this medication is increased in Asian patients, the recommended initial dose is 5 mg. Administration of the 40 mg dose is contraindicated. 7. Patients predisposed to myopathy : The recommended initial dose for patients predisposed to myopathy is 5 mg. Administration of the 40 mg dose of this medication is contraindicated in some of these patients.
Child dose
Pediatric patients with heterozygous familial hypercholesterolemia (ages 10 to 17 years): The usual dosage range is 5 mg to 20 mg once daily. (There are no clinical data on administering doses higher than 20 mg to pediatric patients.) The dose should be adjusted individually according to the recommended treatment goal for each patient. The dose should be adjusted at intervals of 4 weeks or more. Safety and efficacy have not been established in children under 10 years of age.

Ingredients

Manufacturer
Daewon Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of dyslipidemia, inhibition of atherosclerosis progression, and prevention of cardiovascular disease

  • Hypercholesterolemia
  • heterozygous familial hypercholesterolemia
  • mixed dyslipidemia
  • homozygous familial hypercholesterolemia
  • dysbetalipoproteinemia
  • increased high-sensitive C-reactive protein
  • hypertension
  • low HDL-cholesterol levels
  • smoking
  • family history of early coronary heart disease
View approved original text

This medication is used as an adjunct when dietary changes and exercise alone are insufficient to control primary hypercholesterolemia and mixed dyslipidemia. It is also beneficial as an adjunct to diet or other lipid-lowering therapy in patients with homozygous familial hypercholesterolemia. It effectively lowers total cholesterol and LDL-cholesterol levels in patients with hypercholesterolemia, thereby slowing the progression of atherosclerosis. In pediatric patients aged 10 to 17 with elevated LDL-cholesterol levels, it can also be used as an adjunct to dietary management. It is helpful in patients with primary dysbetalipoproteinemia and contributes to the reduction of stroke, myocardial infarction, and revascularization risk in middle-aged patients with high-sensitive C-reactive protein levels and additional cardiovascular risk factors. Therefore, this drug is effectively used for various dyslipidemias and patients at risk for cardiovascular diseases.

How to take

Adult dose

1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medication and continue it throughout the treatment period. This medication may be taken at any time of day, with or without food. The initial dose is 5 mg once daily. If a greater reduction in LDL cholesterol is required, the dose may be adjusted to a maintenance dose. The maintenance dose is 10 mg once daily, which controls the condition in most patients. The maintenance dose should be adjusted as appropriate at intervals of 4 weeks or more according to LDL cholesterol levels, treatment goals, and the patient's response, and may be increased to a maximum of 20 mg per day. 3. Elderly patients : No dosage adjustment is necessary. 4. Patients with renal impairment : No dosage adjustment is necessary for patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Particular caution should be exercised when administering 20 mg of this medication to patients with moderate renal impairment. 5. Patients with hepatic impairment : No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer this medication to patients with active liver disease. 6. Race : Because systemic exposure to this medication is increased in Asian patients, the recommended initial dose is 5 mg. Administration of the 40 mg dose is contraindicated. 7. Patients predisposed to myopathy : The recommended initial dose for patients predisposed to myopathy is 5 mg. Administration of the 40 mg dose of this medication is contraindicated in some of these patients.

Child dose

Pediatric patients with heterozygous familial hypercholesterolemia (ages 10 to 17 years): The usual dosage range is 5 mg to 20 mg once daily. (There are no clinical data on administering doses higher than 20 mg to pediatric patients.) The dose should be adjusted individually according to the recommended treatment goal for each patient. The dose should be adjusted at intervals of 4 weeks or more. Safety and efficacy have not been established in children under 10 years of age.

Precautions

This drug should not be used in certain patients. For example, individuals allergic to any component of this medication, those with severely impaired liver function, those with muscle disorders, those taking certain immunosuppressants, individuals with significantly reduced kidney function, pregnant or nursing women, and those at high risk for muscle diseases should not take this drug. It is important to periodically check liver function and muscle condition while taking this drug. Particularly, individuals who consume large amounts of alcohol, have a history of liver disease, have hypothyroidism, have reduced kidney function, are elderly (over 70 years), or are taking certain medications should exercise additional caution. If symptoms such as muscle pain, muscle weakness, or cramps occur, report to a doctor immediately and get examined. If these symptoms are severe or if muscle enzyme levels rise significantly, discontinuation of the drug may be necessary. This drug contains lactose, so individuals with lactose intolerance should not take it. There may be drug interactions when taken with certain medications, so if currently taking any drugs, they must inform their doctor or pharmacist. Women who are pregnant or planning to become pregnant must use appropriate contraception, and if pregnancy is confirmed, they should discontinue taking this drug immediately. Additionally, nursing women should avoid taking this drug for safety reasons. There is no specific antidote in case of overdose, so treatment should be symptomatic while monitoring liver function and muscle enzyme levels. Caution is needed while driving or operating machinery due to possible dizziness. Finally, this drug may rarely cause serious skin reactions, liver damage, or muscle adverse reactions, so if new symptoms appear, consult medical personnel immediately.

Side effects

Hypersensitivity reactions including angioedema, diabetes, headache, dizziness, constipation, nausea, abdominal pain, pancreatitis, pruritus, rash, urticaria, myalgia, myopathy, rhabdomyolysis, weakness, polyneuropathy, amnesia, peripheral neuropathy, myasthenia gravis, cough, dyspnea, diarrhea, oculobulbar weakness, thrombocytopenia, jaundice, hepatitis, elevated transaminases, Stevens-Johnson syndrome, eosinophilia with systemic symptoms associated drug reaction syndrome, drug rash resembling psoriasis, lupus-like syndrome, muscle rupture, arthralgia, immune-mediated necrotizing myopathy, hematuria, edema, depression, sleep disturbances, interstitial lung disease, sexual dysfunction, gynecomastia, fatal and non-fatal liver failure, cognitive impairment, increased ALT, chest pain, muscle cramps, gout, erectile dysfunction, numbness, paresthesia, chest discomfort, loss of appetite, abdominal distension, fainting, generalized pain, fatigue

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly closed container to prevent exposure to air or moisture. It is best to store the drug at room temperature between 1 to 30 degrees Celsius. Proper storage will help maintain the effectiveness of the medication.

Appearance and packaging

Appearance

Yellow round film-coated tablet

Package unit

Domestic: 28 tablets (14 tablets/PTP X 2), Export: 28 tablets (14 tablets/PTP X 2)

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.